Specialist Medical Omnibuses Launched

US-based MDLinx has announced a new Omnibus offering for international pharmaceutical market research, among specialty physicians in eight treatment areas.

The eight hard-to-reach specialties and their omnibus brand names are Oncology (Oncobus), Rheumatology (Rheumbus), Psychiatry (Psychbus), Neurology (Neurobus), Endocrinology (Endobus), Cardiology (Cardiobus), Infectious Disease (IDbus) and General Medicine (GPbus).

The surveys will run monthly and pool questions from participating research companies, with a minimum of three questions per company put to 350 specialty physicians from the USA, Japan, Germany, France, UK, Spain, and Italy, all part of MDLinx's MRA Verified worldwide panel.

Questions are submitted in English by the first business day of the month, and then translated and fielded, with answers returned in about one week.

William Hoover, Director of Market Research, comments: 'Our unsurpassed reach and exclusive deep relationships with physician specialists in the USA, EU, and Japan allow us to be the only company to offer a monthly worldwide omnibus in these specialties.' CTO Craig Overpeck adds: 'Market researchers are under two pressures in today's economic environment. They need to access specialists in all top markets quickly to explore demand and they need to do it without increasing their budgets. Rapid, low-cost access to specialists in the 7 top markets simultaneously was unthinkable - until now.'

Founded in 1999, MDLinx is a division of M3 USA. Details of the new service are online at www.mdlinx.com/mr/omni .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• MDLinx
• All news